Published in Infect Immun on March 01, 2004
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J (2008) 3.02
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med (2010) 2.61
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med (2007) 1.78
Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J (2008) 1.76
Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J (2009) 1.63
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials (2007) 1.58
The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun (2004) 1.44
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials (2006) 1.36
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol (2008) 1.34
Interaction of malaria with a common form of severe thalassemia in an Asian population. Proc Natl Acad Sci U S A (2009) 1.29
A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun (2006) 1.27
The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One (2009) 1.24
What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J (2009) 1.18
The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS One (2011) 1.14
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother (2012) 1.13
How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol (2009) 1.11
A comparative study of the genetic diversity of the 42kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax. Infect Genet Evol (2006) 1.07
Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine (2008) 1.03
Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr Infect Dis J (2011) 1.01
Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis (2013) 1.01
Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun (2013) 1.00
Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting. Infect Immun (2009) 1.00
Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development. Infect Immun (2011) 0.94
Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. Infect Immun (2006) 0.94
Inhibition of erythrocyte invasion and Plasmodium falciparum merozoite surface protein 1 processing by human immunoglobulin G1 (IgG1) and IgG3 antibodies. Infect Immun (2009) 0.91
Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response. Infect Immun (2009) 0.89
Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. Am J Trop Med Hyg (2007) 0.85
Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. PLoS One (2011) 0.85
Suppression of Plasmodium falciparum by serum collected from a case of Plasmodium vivax infection. Malar J (2008) 0.84
Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One (2011) 0.82
Decreased growth rate of P. falciparum blood stage parasitemia with age in a holoendemic population. J Infect Dis (2013) 0.82
Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection. Malar J (2009) 0.81
Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection. Malar J (2010) 0.81
Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection. Malar J (2012) 0.81
Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum. Parasitol Res (2010) 0.78
Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies. Exp Parasitol (2006) 0.76
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol (1993) 3.99
Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis (1996) 3.49
Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature (1985) 3.19
Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol (1992) 3.12
Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med (1994) 2.94
Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med (1997) 2.92
Immunization against malaria with a recombinant protein. Parasite Immunol (1994) 2.89
Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol (1994) 2.71
A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun (1996) 2.60
Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol Biochem Parasitol (1987) 2.56
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol (1999) 2.39
A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg (1998) 2.33
Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci U S A (1996) 2.25
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun (1999) 2.16
Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. Nat Med (2000) 2.15
Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia (1999) 2.01
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol (2001) 1.87
The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun (2002) 1.56
Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun (2000) 1.43
Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: relationships with clinical malaria and with entomological inoculation rates. Parasite Immunol (1999) 1.34
Humoral response to Plasmodium falciparum Pf155/ring-infected erythrocyte surface antigen and Pf332 in three sympatric ethnic groups of Burkina Faso. Am J Trop Med Hyg (1998) 1.32
Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J Immunol (1998) 1.27
Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two-site radioimmunoassay. Parasite Immunol (1987) 1.19
Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Infect Immun (1995) 1.14
Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors. Infect Immun (2000) 0.97
A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 10.65
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA (2005) 4.57
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Innate immunity to malaria. Nat Rev Immunol (2004) 4.19
Altitude-dependent and -independent variations in Plasmodium falciparum prevalence in northeastern Tanzania. J Infect Dis (2005) 3.75
Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res (2004) 3.63
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis (2002) 3.22
Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 3.07
Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One (2009) 2.94
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Does malaria suffer from lack of memory? Immunol Rev (2004) 2.66
Incidence of HIV infection in stable sexual partnerships: a retrospective cohort study of 1802 couples in Mwanza Region, Tanzania. J Acquir Immune Defic Syndr (2002) 2.60
A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites. J Biol Chem (2005) 2.50
Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J Infect Dis (2002) 2.39
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet (2007) 2.36
Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30
Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem (2007) 2.23
A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science (2002) 2.20
Serological markers suggest heterogeneity of effectiveness of malaria control interventions on Bioko Island, equatorial Guinea. PLoS One (2011) 2.18
The motor complex of Plasmodium falciparum: phosphorylation by a calcium-dependent protein kinase. J Biol Chem (2008) 2.14
Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. J Immunol (2002) 2.12
Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med (2011) 2.04
IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog (2008) 2.01
Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics (2004) 1.88
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model. PLoS Comput Biol (2007) 1.87
Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology (2009) 1.87
Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat Rev Immunol (2007) 1.84
Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog (2009) 1.81
Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect (2002) 1.81
Adverse birth outcomes in United Republic of Tanzania--impact and prevention of maternal risk factors. Bull World Health Organ (2007) 1.78
Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol (2007) 1.78
Optimal immune responses: immunocompetence revisited. Trends Ecol Evol (2005) 1.78
Effective induction of high-titer antibodies by viral vector vaccines. Nat Med (2008) 1.76
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS One (2009) 1.68
Impact of a decline in Colorado Medicaid managed care enrollment on access and quality of preventive primary care services. Pediatrics (2005) 1.66
Variation in the expression of a Plasmodium falciparum protein family implicated in erythrocyte invasion. Infect Immun (2002) 1.64
Epigenetic silencing of Plasmodium falciparum genes linked to erythrocyte invasion. PLoS Pathog (2007) 1.63
Association of sub-microscopic malaria parasite carriage with transmission intensity in north-eastern Tanzania. Malar J (2011) 1.63
Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol (2006) 1.62
The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog (2007) 1.61
The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun (2002) 1.56
Malaria parasite actin filaments are very short. J Mol Biol (2005) 1.56
Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites. PLoS Genet (2012) 1.55
Use of data from HIV counselling and testing services for HIV surveillance in Africa. Lancet (2007) 1.54
Dual acylation of the 45 kDa gliding-associated protein (GAP45) in Plasmodium falciparum merozoites. Mol Biochem Parasitol (2006) 1.53
Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J Immunol (2003) 1.52
Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem (2002) 1.50
The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection. PLoS One (2013) 1.49
PfEMP1-DBL1alpha amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (2007) 1.47
Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun (2003) 1.44
The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun (2004) 1.44
Differential induction of TGF-beta regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J Immunol (2003) 1.44
Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J Immunol (2010) 1.43
Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes. Genome Res (2009) 1.42
NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. J Immunol (2010) 1.41
Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog (2006) 1.40
Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog (2010) 1.39
The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony. Eukaryot Cell (2009) 1.39
Comparison of HIV prevalences in community-based and antenatal clinic surveys in rural Mwanza, Tanzania. AIDS (2002) 1.38
Genome wide gene amplifications and deletions in Plasmodium falciparum. Mol Biochem Parasitol (2007) 1.37
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
IFN-γ-producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell accumulation within the brain. J Immunol (2012) 1.34
N-myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem (2008) 1.33
Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog (2006) 1.31
A comprehensive evaluation of rodent malaria parasite genomes and gene expression. BMC Biol (2014) 1.31
Continuing intense malaria transmission in northern Uganda. Am J Trop Med Hyg (2011) 1.30
Essential role for IL-27 receptor signaling in prevention of Th1-mediated immunopathology during malaria infection. J Immunol (2010) 1.29
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites. A role for microbial raft proteins in apicomplexan vacuole biogenesis. J Biol Chem (2003) 1.27
Similarities and differences in motion processing between the human and macaque brain: evidence from fMRI. Neuropsychologia (2003) 1.26
Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int J Parasitol (2003) 1.26
Apical expression of three RhopH1/Clag proteins as components of the Plasmodium falciparum RhopH complex. Mol Biochem Parasitol (2005) 1.26
Site-specific N-terminal labelling of proteins in vitro and in vivo using N-myristoyl transferase and bioorthogonal ligation chemistry. Chem Commun (Camb) (2007) 1.25
Serological responses among individuals in areas where both schistosomiasis and malaria are endemic: cross-reactivity between Schistosoma mansoni and Plasmodium falciparum. J Infect Dis (2003) 1.25
Neuropathogenesis of human and murine malaria. Trends Parasitol (2010) 1.24
Adaptation of the genetically tractable malaria pathogen Plasmodium knowlesi to continuous culture in human erythrocytes. Proc Natl Acad Sci U S A (2012) 1.24
Identification of new PNEPs indicates a substantial non-PEXEL exportome and underpins common features in Plasmodium falciparum protein export. PLoS Pathog (2013) 1.24
Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol (2013) 1.22
Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One (2011) 1.22
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol (2004) 1.22
Prolonged neutrophil dysfunction after Plasmodium falciparum malaria is related to hemolysis and heme oxygenase-1 induction. J Immunol (2012) 1.21
The MTIP-myosin A complex in blood stage malaria parasites. J Mol Biol (2005) 1.20
Homeostatic regulation of T effector to Treg ratios in an area of seasonal malaria transmission. Eur J Immunol (2009) 1.20
Heterogeneous human NK cell responses to Plasmodium falciparum-infected erythrocytes. J Immunol (2005) 1.20